Top news of the week: 28.04.2020.
Biotechnology, Clinical research, Antibody, Pharmacology, Vaccination, RNA
Healthcare
RT @BioPharmaMike: Pleased to have been asked in my new role as Global Head of Thought Leadership at @DRGinsights, part of @clarivate, to write the foreword for the new Swiss Biotech report which highlights all progress in Swiss #biotech download here: https://t.co/qGHXRLnroi
OpenMedia Info
To strengthen and promote the Swiss biotech industry, the Swiss Biotech Association collaborates with numerous partners and life science clusters globally under the brand Swiss …
BREAKING: Data on Gilead’s remdesivir, released by accident, show no benefit for #coronavirus patients https://t.co/rstX36a7lA via @statnews These are data from the China study. $GILD
OpenNew data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hope
The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients in China with Covid-19 or prevent them from dying.
RT @adamfeuerstein: The world wants answers on Gilead’s #Covid19 drug. Experts worry next studies may increase uncertainty https://t.co/GqQPEALNPy @matthewherper and I preview this week's expected readout of Gilead's remdesivir "severe" study, with comments from a cast of characters.
OpenThe world wants answers on Gilead’s Covid-19 drug. Experts worry next studies may increase uncertainty
For weeks, the world has been eagerly awaiting clinical trial results for one experimental drug, remdesivir, to treat Covid-19.
Here are some of the drugs being developed to attack COVID-19 and the virus that causes it. https://t.co/dXREWVr1Dp
OpenThree Ways to Make Coronavirus Drugs In a Hurry
With no time to make treatments from scratch, researchers search for existing compounds that deflect harm
RT @NYTScience: A team of 50 scientists evaluated 14 available tests for coronavirus antibodies. Only three passed muster: “Those numbers are just unacceptable.” https://t.co/Cu1r4iU2zR
OpenCoronavirus Antibody Tests: Can You Trust the Results?
A team of scientists worked around the clock to evaluate 14 antibody tests. A few worked as advertised. Most did not.
Biopharma Update on the Novel Coronavirus: April 21 https://t.co/2i5ypPGtsI https://t.co/VnBZ5ZrFX2
OpenBiopharma Update on the Novel Coronavirus: April 21
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 21, 2020.
Special Report: Countries, companies risk billions in race for coronavirus vaccine https://t.co/dpRGlwezWH
OpenSpecial Report: Countries, companies risk billions in race for coronavirus vaccine
In the race to develop a vaccine to end the COVID-19 pandemic, governments, charities and Big Pharma firms are sinking billions of dollars into bets with extraordinarily low odds of success.
BioSpace Global Roundup, April 23
Biopharma and life sciences groups from across the globe provide updates on their business and pipelines.